GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (NAS:BCTX) » Definitions » Shiller PE Ratio

BriaCell Therapeutics (BriaCell Therapeutics) Shiller PE Ratio : (As of May. 14, 2024)


View and export this data going back to . Start your Free Trial

What is BriaCell Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


BriaCell Therapeutics Shiller PE Ratio Historical Data

The historical data trend for BriaCell Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Shiller PE Ratio Chart

BriaCell Therapeutics Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BriaCell Therapeutics Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BriaCell Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, BriaCell Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Shiller PE Ratio falls into.



BriaCell Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

BriaCell Therapeutics's E10 for the quarter that ended in Jan. 2024 is calculated as:

For example, BriaCell Therapeutics's adjusted earnings per share data for the three months ended in Jan. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jan. 2024 (Change)*Current CPI (Jan. 2024)
=-0.71/125.4675*125.4675
=-0.710

Current CPI (Jan. 2024) = 125.4675.

BriaCell Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201404 -8.900 98.920 -11.289
201407 -125.175 99.315 -158.137
201410 -0.309 99.473 -0.390
201501 -9.427 98.209 -12.044
201504 -2.495 99.710 -3.140
201507 -1.551 100.579 -1.935
201510 -2.295 100.500 -2.865
201601 -2.147 100.184 -2.689
201604 -2.390 101.370 -2.958
201607 -2.018 101.844 -2.486
201610 -2.236 102.002 -2.750
201701 -2.290 102.318 -2.808
201704 -4.397 103.029 -5.355
201707 -9.421 103.029 -11.473
201710 -2.339 103.424 -2.838
201801 -2.432 104.056 -2.932
201804 -2.336 105.320 -2.783
201807 6.977 106.110 8.250
201810 -1.472 105.952 -1.743
201901 -2.216 105.557 -2.634
201904 -1.929 107.453 -2.252
201907 -2.641 108.243 -3.061
201910 -1.830 107.927 -2.127
202001 -1.975 108.085 -2.293
202004 -0.699 107.216 -0.818
202007 -1.334 108.401 -1.544
202010 -0.540 108.638 -0.624
202101 -0.300 109.192 -0.345
202104 0.630 110.851 0.713
202107 -1.055 112.431 -1.177
202110 -1.810 113.695 -1.997
202201 0.710 114.801 0.776
202204 -0.650 118.357 -0.689
202207 -0.030 120.964 -0.031
202210 -0.070 121.517 -0.072
202301 -0.770 121.596 -0.795
202304 -0.320 123.571 -0.325
202307 -0.150 124.914 -0.151
202310 -0.500 125.310 -0.501
202401 -0.710 125.468 -0.710

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BriaCell Therapeutics  (NAS:BCTX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


BriaCell Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics (BriaCell Therapeutics) Business Description

Traded in Other Exchanges
Address
235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.
Executives
Jamieson Bondarenko director 402-1 SCOTT ST.`, TORONTO A6 M5E 1A1
Jane A Gross director 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Rebecca Taub director 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gadi Levin officer: CFO & Secretary MOSHAV AZRIEL 108, LEV HASHARON L3 4582500
Priore Giuseppe Del officer: Chief Medical Officer 44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Williams V. Williams director, officer: President & CEO 620 SOUTH EAGLE ROAD, HAVERTOWN PA 19083
Martin E. Schmieg director 201 S. 25TH STREET, APT. #521, PHILADELPHIA PA 19103
Miguel A. Lopez-lago officer: Chief Scientific Officer 2401 PENNSYLVANIA AVE., APT #12A6, PHILADELPHIA PA 19130
Vaughn C. Embro-pantalony director P.O. BOX 58, 285 SUNSET BLVD, THORNBURY A6 N0H 2P0
Marc Lustig director 4177 ROCKRIDGE ROAD, WEST VANCOUVER A1 V7W 1A3

BriaCell Therapeutics (BriaCell Therapeutics) Headlines

From GuruFocus

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

By sperokesalga sperokesalga 02-10-2023